Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101

AA Miller, DJ Murry, K Owzar, DR Hollis… - Journal of clinical …, 2007 - ascopubs.org
Purpose We investigated dose and pharmacokinetics of erlotinib in patients with hepatic
dysfunction or renal dysfunction. Patients and Methods Patients were assigned to one of …
被引用次数：86 相关文章
[PDF] academia.edu

[PDF][PDF] Phase I and Pharmacokinetic Study of Erlotinib for Solid Tumors in Patients With Hepatic or Renal Dysfunction: CALGB 60101

AA Miller, DJ Murry, K Owzar, DR Hollis, LD Lewis… - J Clin Oncol, 2007 - academia.edu
Phase I and Pharmacokinetic Study of Erlotinib for Solid Tumors in Patients With Hepatic or
Renal Dysfunction: CALGB 60101 Page 1 Phase I and Pharmacokinetic Study of Erlotinib for …

Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.

AA Miller, DJ Murry, K Owzar, DR Hollis… - Journal of Clinical …, 2007 - europepmc.org
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal
dysfunction: CALGB 60101. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …

Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101

AA Miller, DJ Murry, K Owzar, DR Hollis… - Journal of Clinical …, 2007 - experts.nebraska.edu
Purpose: We investigated dose and pharmacokinetics of erlotinib in patients with hepatic
dysfunction or renal dysfunction. Patients and Methods: Patients were assigned to one of …

Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101

AA Miller, DJ Murry, K Owzar… - Journal of clinical …, 2007 - pubmed.ncbi.nlm.nih.gov
Purpose We investigated dose and pharmacokinetics of erlotinib in patients with hepatic
dysfunction or renal dysfunction. Patients and methods Patients were assigned to one of …

Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101

AA Miller, DJ Murry, K Owzar, DR Hollis… - Journal of Clinical …, 2007 - pure.psu.edu
Purpose: We investigated dose and pharmacokinetics of erlotinib in patients with hepatic
dysfunction or renal dysfunction. Patients and Methods: Patients were assigned to one of …

Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101

AA Miller, DJ Murry, K Owzar… - Journal of Clinical …, 2007 - ohiostate.elsevierpure.com
Purpose: We investigated dose and pharmacokinetics of erlotinib in patients with hepatic
dysfunction or renal dysfunction. Patients and Methods: Patients were assigned to one of …

[引用][C] Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101

AA MILLER, DJ MURRY… - Journal of clinical …, 2007 - pascal-francis.inist.fr
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or
renal dysfunction : CALGB 60101 CNRS Inist Pascal-Francis CNRS Pascal and Francis …

Phase I and Pharmacokinetic Study of Erlotinib for Solid Tumors in Patients With Hepatic or Renal Dysfunction: CALGB 60101

AA Miller, DJ Murry, K Owzar, DR Hollis… - Journal of Clinical …, 2007 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> We investigated dose and
pharmacokinetics of erlotinib in patients with hepatic dysfunction or renal dysfunction.</jats …
[PDF] academia.edu

[PDF][PDF] Phase I and Pharmacokinetic Study of Erlotinib for Solid Tumors in Patients With Hepatic or Renal Dysfunction: CALGB 60101

AA Miller, DJ Murry, K Owzar, DR Hollis, LD Lewis… - J Clin Oncol, 2007 - academia.edu
Phase I and Pharmacokinetic Study of Erlotinib for Solid Tumors in Patients With Hepatic or
Renal Dysfunction: CALGB 60101 Page 1 Phase I and Pharmacokinetic Study of Erlotinib for …